[Effects of vascular endothelial growth factor D on the signaling cascade of sentinel lymphatic endothelial cells from melanoma patients undergoing sentinel lymphadenectomy].
Advances in surgical treatment, including sentinel lymphadenectomy, permit the pathologic staging of regional lymph nodes most likely to contain metastasis by identifying afferent lymphatic channels, which specifically drain the primary tumor site. Recently, a new member of the angiogenic molecule in VEGF family, VEGF-D, has been identified that induces lymphangiogenesis via high-affinity binding to VEGFR-3. VEGF-D is predominantly expressed in lymphatic endothelium. We have previously developed a novel method for the isolation of anatomically-defined lymphatic endothelial cells (LECs) from human sentinel lymphatic channel during SLN biopsy. The effect of VEGF-D on the extracellular signal-regulated kinases (Erk)-1/2 and Akt signaling pathway was examined by Western blot analysis. VEGF-D (500 ng/ml) apparently upregulated phospho-p44/phospho-p42 activity in human isolated LECs by Western blot analysis, while phospho-Akt activity was not at all changed by VEGF-D exposure without the change of total p44/p42 and Akt expression. U0126 (20 microM), the MEK1/2 inhibitor, could completely block the VEGF-D induced phospholylation of Erk1/2 signaling pathway. These data demonstrate that VEGF-D induces p44/p42 in human LECs and suggests that this signaling pathway activation may be important in LEC biology and lymphoangiogenesis, which may lead to the progression of new strategies of cancer treatment.
Kawai
Yoshiko
Y
Dept. of Surgical Oncology, University of Texas MD Anderson Cancer Center, USA.
Takeda
Akihiko
A
Gershenwald
J E
JE
D004729:Endothelium, Lymphatic / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008545:Melanoma / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000187:drug effects; D021701:Sentinel Lymph Node Biopsy; D015398:Signal Transduction; D042643:Vascular Endothelial Growth Factor D / Q000494:pharmacology*
D042643:Vascular Endothelial Growth Factor D; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases